Satellos Bioscience Inc. (MSCL.TO)
- Previous Close
0.4400 - Open
0.4500 - Bid 0.4850 x --
- Ask 0.4950 x --
- Day's Range
0.4500 - 0.4950 - 52 Week Range
0.2900 - 0.8000 - Volume
29,150 - Avg. Volume
80,719 - Market Cap (intraday)
54.14M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.20
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company's MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
satellos.comRecent News: MSCL.TO
Performance Overview: MSCL.TO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MSCL.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MSCL.TO
Valuation Measures
Market Cap
54.14M
Enterprise Value
7.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.33
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.28%
Return on Equity (ttm)
-72.15%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.89M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
39.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.25M
Research Analysis: MSCL.TO
Company Insights: MSCL.TO
MSCL.TO does not have Company Insights